Iterum Therapeutics PLC
NASDAQ:ITRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Iterum Therapeutics PLC
Interest Expense
Iterum Therapeutics PLC
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Interest Expense
$9.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
